Proteostasis Therapeutics, Inc. (PTI)
(Delayed Data from NSDQ)
$1.08 USD
+0.07 (6.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.07 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
Kineta, Inc. [PTI]
Reports for Purchase
Showing records 1 - 20 ( 24 total )
Company: Kineta, Inc.
Industry: Medical - Biomedical and Genetics
CHOICES Ex Vivo Data Expected in 4Q20 With Clinical Study Initiation in YE20; Reit Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: Kineta, Inc.
Industry: Medical - Biomedical and Genetics
CFTR Modulator Progress and CHOICES Trial Dosing Expected 2H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: Kineta, Inc.
Industry: Medical - Biomedical and Genetics
Prospect for Therapeutic Diversification in Treating CF, With Dosing in CHOICES Trial Expected 2H20; Reit Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: Kineta, Inc.
Industry: Medical - Biomedical and Genetics
Believe Phase 2 Topline Is More Positive Than Perceived by the Street; Reit Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: Kineta, Inc.
Industry: Medical - Biomedical and Genetics
Spotlight on NACFC 2019: Hot Topics and Abstracts of Interest
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: Kineta, Inc.
Industry: Medical - Biomedical and Genetics
Doublet, Triplet CFTR Modulator Combinations Continue Development; Reducing PT to $8, Accounting for Financing Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: Kineta, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Kineta, Inc.
Industry: Medical - Biomedical and Genetics
Genentech Deal Further Validates Discovery Platform; We Believe
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Company: Kineta, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Kineta, Inc.
Industry: Medical - Biomedical and Genetics
Spotlight on NACFC 2018: Hot Topics and Abstracts of Interest
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: Kineta, Inc.
Industry: Unclassified
Price: 25.00
Company: Kineta, Inc.
Industry: Unclassified
Price: 10.00
Company: Kineta, Inc.
Industry: Unclassified
Takeaways From This Year?s European Cystic Fibrosis Basic Science Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: Kineta, Inc.
Industry: Unclassified
Positive result for the amplifier PTI428 elevates the possibility of a novel mechanism aside
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Company: Kineta, Inc.
Industry: Unclassified
Reflections From the North American Cystic Fibrosis Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Company: Kineta, Inc.
Industry: Unclassified
Keeping Up Steady Progress Towards In-House Combo
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Company: Kineta, Inc.
Industry: Unclassified
Price: 10.00
Company: Kineta, Inc.
Industry: Unclassified
Update from NACFC: Amplifier at Bat, and Triple on Deck
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Company: Kineta, Inc.
Industry: Unclassified
Spotlight on NACFC 2016: Hot Topics and Abstracts of InterestThis report contains brief updates on the following: NVLS, PRQR, PTI, VRTX. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: Kineta, Inc.
Industry: Unclassified
Price: 75.00